# Claris Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/claris-bio

- Industry: Biotechnology
- Headquarters: Jersey City, US
- Website: www.clarisbio.com
- Total disclosed funding: $128M
- Latest round: Series B (Jul 28, 2026)
- Investors on record: 10

## About

Based in the US, Claris Biotherapeutics, Inc. operates as a provider of topical formulation to deal with corneal issues. Founded in 2018 and based in New Jersey, US, Claris Biotherapeutics, Inc. operates as a biotechnology company that is focused on corneal disease therapies. Stephen Brady appointed President and Chief Executive Officer, Brian Baum named Chief Commercial Officer, and Marc de Garidel appointed Chairman of the Board. In July 2026, Claris Biotherapeutics, Inc. raised USD 118 million in series B funding co-led by Catalio Capital Management and Samsara BioCapital, with participation from Adage Capital Management, ADAR1 Capital Management, Aisling Capital, Sofinnova Investments, Novo Holdings, Janus Henderson Investors, and Mass General Brigham Ventures. 

The company offers a wide range of treatment solutions to treat corneal ulcers, dry eye disease, corneal edema, microbial keratitis, thermal burn, neurotrophic keratitis, and many others. For the treatment of NK, Claris has created a human recombinant dHGF called CSB-001, which is used topically as a 0.1% ophthalmic solution.

The company plans to use the July 2026 funding to complete clinical studies, support pivotal trials for limbal stem cell deficiency, and prepare for commercialization.

## Funding rounds

- Series B, Jul 28, 2026, $118M — Sofinnova Investments, Aisling Capital, Adage Capital Management, Mass General Brigham Ventures, Novo Holdings, Janus Henderson Investors, Samsara BioCapital, Catalio Capital Management, ADAR1 Capital Management
- Series A, Dec 28, 2023, $10M — Mass General Brigham Ventures, Novo Holdings, RA Capital Management, Janus Henderson Investors

## Investors

- Mass General Brigham Ventures (https://capitalatlas.ai/funds/mass-general-brigham-ventures) — Series A, Series B
- Novo Holdings — Series A, Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A
- Janus Henderson Investors — Series A, Series B
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series B
- Aisling Capital (https://capitalatlas.ai/funds/aisling-capital) — Series B
- Adage Capital Management — Series B
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series B
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series B
- ADAR1 Capital Management (https://capitalatlas.ai/funds/adar1-capital-management) — Series B